KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Invested Capital (2016 - 2025)

Nektar Therapeutics has reported Invested Capital over the past 16 years, most recently at $89.8 million for Q4 2025.

  • Quarterly results put Invested Capital at $89.8 million for Q4 2025, up 47.9% from a year ago — trailing twelve months through Dec 2025 was $89.8 million (up 47.9% YoY), and the annual figure for FY2025 was $89.8 million, up 47.9%.
  • Invested Capital for Q4 2025 was $89.8 million at Nektar Therapeutics, up from $85.1 million in the prior quarter.
  • Over the last five years, Invested Capital for NKTR hit a ceiling of $994.5 million in Q1 2021 and a floor of -$24.2 million in Q2 2025.
  • Median Invested Capital over the past 5 years was $178.2 million (2023), compared with a mean of $321.7 million.
  • Peak annual rise in Invested Capital hit 74.06% in 2025, while the deepest fall reached 130.38% in 2025.
  • Nektar Therapeutics' Invested Capital stood at $679.5 million in 2021, then crashed by 46.04% to $366.6 million in 2022, then tumbled by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024, then surged by 47.9% to $89.8 million in 2025.
  • The last three reported values for Invested Capital were $89.8 million (Q4 2025), $85.1 million (Q3 2025), and -$24.2 million (Q2 2025) per Business Quant data.